Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines (Q34653218)

3 August 2017

Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines (English)

1 reference

3 August 2017

0 references

1 reference

1 reference

United States of America

1 reference

Heikki Peltola

1

1 reference

3 August 2017

Prasad S Kulkarni

2

1 reference

3 August 2017

Subhash V Kapre

3

1 reference

3 August 2017

Mikko Paunio

4

1 reference

3 August 2017

Suresh S Jadhav

5

1 reference

3 August 2017

Rajeev M Dhere

6

1 reference

3 August 2017

language of work or name

English

0 references

publication date

10 July 2007

1 reference

Clinical Infectious Diseases

3 August 2017

1 reference

3 August 2017

45

1 reference

3 August 2017

459-466

1 reference

3 August 2017

4

1 reference

Two successive outbreaks of mumps in Nova Scotia among vaccinated adolescents and young adults

3 August 2017

1 reference

Mumps outbreak in a highly vaccinated school population. Evidence for large-scale vaccination failure

21 January 2018

1 reference

Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England.

21 January 2018

1 reference

Comparison of the efficacy of various strains of mumps vaccine: a school survey

21 January 2018

1 reference

Mumps outbreak in a highly vaccinated population

21 January 2018

1 reference

Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland

21 January 2018

1 reference

Why the next census needs to ask about language

21 January 2018

1 reference

Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century

21 January 2018

1 reference

Mapping antigenic diversity and strain specificity of mumps virus: a bioinformatics approach

21 January 2018

1 reference

Live, attenuated mumps-virus vaccine

21 January 2018

1 reference

Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins

21 January 2018

1 reference

Mumps vaccine complications: which strain?

21 January 2018

1 reference

Neurologic disorders after measles-mumps-rubella vaccination.

21 January 2018

1 reference

Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation

21 January 2018

1 reference

Field evaluation of live virus mumps vaccine

21 January 2018

1 reference

Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population

21 January 2018

1 reference

Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials

21 January 2018

1 reference

Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study

21 January 2018

1 reference

Comparison of the Urabe Am 9-Schwarz and Jeryl Lynn-Moraten combinations of mumps-measles vaccines in young children

21 January 2018

1 reference

The Urabe AM9 mumps vaccine is a mixture of viruses differing at amino acid 335 of the hemagglutinin-neuraminidase gene with one form associated with disease.

21 January 2018

1 reference

Mumps in the region of Rijeka, Croatia

21 January 2018

1 reference

Aseptic meningitis in a large MMR vaccine campaign (590,609 people) in Curitiba, Paraná, Brazil, 1998.

21 January 2018

1 reference

Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age.

21 January 2018

1 reference

IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy

21 January 2018

1 reference

Vaccine safety versus vaccine efficacy in mass immunisation programmes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/520028

1 reference

3 August 2017

1 reference